Does Semax interact with alcohol?
No published studies have directly investigated the combination of Semax and alcohol—neither in animals nor in humans. However, a lack of studied interactions does not equate to confirmed safety. Anyone combining Semax with alcohol does so without the support of any controlled studies.
Alcohol acts as a central nervous system depressant. It enhances the activity of GABA receptors—increasing the brain's calming, inhibitory signals—while simultaneously inhibiting the activity of NMDA glutamate receptors, reducing the brain's excitatory signals. Put simply, alcohol simultaneously strengthens the brain's brakes and weakens its accelerator.
Semax works in essentially the opposite direction. It enhances glutamatergic synaptic transmission [1], potentiates dopaminergic system responses [2], increases BDNF [3], and activates brain networks associated with vigilance and cognitive performance [4]. Combining substances with opposing effects on the central nervous system raises legitimate questions about whether they might partially neutralize each other, have unpredictable interactions, or under certain circumstances, induce effects stronger than either substance alone.
What can happen after combining Semax with alcohol?
Based on contrasting pharmacological profiles, the most likely outcome of combining Semax with alcohol is the partial cancellation of their mutual effects on brain activity. Alcohol's GABA-enhancing and glutamate-suppressing effects would dampen Semax's cognitive activation, while its dopamine and serotonin modulating effects could unpredictably alter subjective feelings of alcohol intoxication. This is theoretical reasoning based on known pharmacological properties, rather than documented study results of the combination.
One of the pharmacologically significant issues is the documented inhibition of enkephalin-degrading enzymes in human blood by Semax [5]. Enkephalins are the brain's own naturally occurring opioid-like calming peptides. When Semax inhibits the enzymes that break down these peptides, it prolongs their activity—effectively enhancing the brain's natural inhibitory opioid signals. Alcohol also enhances the activity of the opioid system through its own indirect mechanisms. Combining the two substances, both of which increase the activity of the brain's natural opioid system, even through entirely different pathways, could theoretically cause additive central nervous system depression beyond the effect of each substance alone. This is a theoretical concern, not a documented interaction—however, it warrants caution.
Alcohol is also a well-established suppressor of BDNF expression in the brain—particularly in the hippocampus—and it is this suppression of BDNF that is directly linked to alcohol's detrimental effects on memory and learning. Semax's most consistent and potent effect is to increase BDNF in the very same brain regions that alcohol damages most [3], [6]. Whether Semax's BDNF-stimulating effects can significantly counteract alcohol's suppression of BDNF has never been tested. It would be inappropriate to suggest that Semax protects the brain from alcohol's harmful effects without direct evidence.
Does alcohol reduce the effectiveness of Semax?
Alcohol likely diminishes the pro-cognitive effects of Semax during intoxication, given the opposing nature of their actions on the central nervous system. The neuronal activation, improved focus, and enhanced synaptic plasticity that Semax induces through glutamatergic potentiation and dopaminergic modulation would logically be challenged by alcohol's concurrent suppression of these same systems.
From a practical standpoint, combining an activating nootropic with a sedating intoxicant is inherently counterproductive to the goals most people use Semax for – cognitive performance, learning, and focus. Semax's efficacy for these purposes would likely be diminished during co-administration with alcohol, though the precise extent of this effect has not been quantified in any study.
Semax, cannabis, or other recreational substances
No published studies have analyzed Semax in combination with cannabis, cocaine, or other recreational substances. Cannabis primarily acts through cannabinoid receptors and has complex effects on the dopaminergic, GABAergic, and glutamatergic systems—all of which overlap with Semax's pharmacological targets. This makes their combination theoretically unpredictable without specific combination study data.
The dopaminergic-enhancing effect of Semax—its ability to amplify dopaminergic responses [2]—is particularly relevant for any substance affecting dopaminergic signaling. Amplifying an already heightened dopaminergic response could theoretically induce unexpected cardiovascular or psychiatric effects. In the complete absence of evidence, combining Semax with any recreational substance should be considered an inadvisable and potentially unpredictable practice.
Does Semax interact with SSRIs or antidepressants?
No published studies have directly investigated the interaction of Semax with SSRIs—selective serotonin reuptake inhibitors, a commonly prescribed class of antidepressants—or other antidepressants. However, several pharmacological considerations make this combination warrant careful consideration.
SSRIs work by blocking the reuptake of serotonin into nerve cells. By blocking this process, they increase the amount of serotonin available in the synapse—the space between nerve cells—effectively strengthening serotonin signaling.
Semax also increases serotonin turnover in the striatum [2] and has documented antidepressant effects via mechanisms involving serotonergic activation and increased BDNF [7]. The combination of two factors, both enhancing serotonergic activity, raises a theoretical concern for serotonin syndrome—a potentially serious condition caused by excessive serotonin activity in the brain and body. Symptoms can range from agitation, rapid heart rate, and muscle tremors to more severe neurological effects in severe cases.
To be precise about the actual evidence: serotonin syndrome has not been reported in any Semax studies, and its effect on serotonin appears to be modulatory—gently tuning the system—rather than a direct reuptake blockade like SSRIs. The degree of serotonin potentiation by Semax is likely modest compared to a dedicated SSRI, mitigating practical risks. However, with a complete lack of safety data on the combination, individuals currently taking SSRIs, SNRIs, MAOIs, tricyclic antidepressants, or any other medication significantly affecting serotonin levels should discuss Semax use with their prescribing physician before combining these compounds.
A study with neonatal fluvoxamine—analyzing Semax's ability to correct behavioral and neurochemical disorders induced by early SSRI exposure—provides indirect evidence that Semax and SSRIs affect overlapping neurochemical systems [8], which underscores the importance of caution when combining them.
Does Semax interact with Adderall or Vyvanse?
No published studies have investigated Semax in combination with amphetamine-based medications, including Adderall or Vyvanse. This is a combination that warrants extreme caution based on available pharmacological evidence.
The most directly relevant finding is that Semax dramatically potentiates—that is, significantly amplifies—the dopamine-releasing effect of D-amphetamine in animal studies, producing substantially higher peak dopamine levels and more pronounced locomotor stimulation than amphetamine alone [9, 2]. This effect was documented through microdialysis, a technique that directly measures brain fluid chemistry in real time, and represents a biologically relevant interaction, not merely a theoretical concern.
If Semax amplifies the dopamine-releasing effects of D-amphetamine in animal models, there is a rational basis to expect it may also amplify the cardiovascular and stimulant effects of therapeutic amphetamine drugs in humans. This could potentially increase heart rate, blood pressure, anxiety, and the risk of overstimulation beyond therapeutic intent.
This does not mean the combination is definitively dangerous — but it does mean that individuals taking prescribed stimulants like Adderall or Vyvanse should not add Semax without an explicit conversation with their prescribing physician. The dopaminergic-potentiating mechanism is the strongest and most directly documented concern regarding pharmacological interactions across Semax's interaction profile.
Does Semax interact with stimulants in general?
The same concern about dopaminergic potentiation that applies to amphetamine-based drugs essentially extends to other dopamine-mediated stimulants, including methylphenidate (sold under the brand names Ritalin and Concerta) and modafinil, a wakefulness-promoting agent.
Semax amplifies the dopaminergic system's response to stimulation [9]—a property suggesting it sensitizes dopaminergic circuits to respond more intensely to any dopaminergic stimulus, not just amphetamine. Whether this enhancement extends to other stimulant mechanisms has not been directly tested; however, the precautionary principle applies.
Combining Semax with any stimulating medication or supplement without medical supervision is a pharmacologically significant combination with a credible mechanism for potentially enhanced and undesirable stimulation of the cardiovascular and central nervous systems.
Does Semax interact with blood pressure medication?
Semax exhibits documented cardiovascular effects. These include modulation of sympathetic nervous system activity [10], reduction in sympathetic nerve density in blood vessel walls after myocardial infarction [11], antithrombotic effects [12], and changes in blood vessel responsiveness to stress signals [11]. These cardiovascular effects provide a plausible basis for interactions with blood pressure medications, although no study has directly investigated this combination.
The concern is not that Semax dramatically raises or lowers blood pressure on its own—it doesn't appear to do so at the doses studied. Rather, its sympathetically modulating effects could alter how blood pressure-lowering medications—prescribed to reduce blood pressure—work in the body. This could potentially cause an additive lowering of pressure or modify the expected response to the medication.
Individuals taking beta-blockers, ACE inhibitors, calcium channel blockers, or other blood pressure medications should be aware that the cardiovascular effects of Semax have not been studied in the context of concurrent antihypertensive therapy. Consultation with a cardiologist or physician is strongly recommended before adding Semax to a treatment regimen.
What medications should not be combined with Semax?
Based on pharmacological reasoning from available evidence, the combinations requiring the greatest caution are as follows.
Amphetamine-based stimulants like Adderall and Vyvanse raise the most concern due to their documented dopaminergic-enhancing effect shown in animal studies [9]. Serotonin-active medications, including SSRIs, SNRIs, and MAOIs, require caution due to overlapping serotonergic effects and the theoretical risk of excessive serotonin system activation [2]. Anticoagulants and antiplatelet agents—including warfarin, heparin, aspirin, and clopidogrel—raise concerns due to Semax's own documented fibrinolytic and anticoagulant effects, which could amplify bleeding risk when combined with other blood-thinning agents [12]. Antiepileptic drugs used for seizure disorders also warrant caution considering the EEG changes observed in some patients after Semax use [13] and the general principle that neuronal excitability-modifying compounds may have unpredictable interactions with antiseizure medications.
The list is based on pharmacological reasoning rather than documented case reports, as no formal drug interaction studies for Semax have been published.
Does Semax interact with other nootropics?
No published research has formally investigated Semax in combination with other nootropic compounds. However, pharmacological reasoning from the profiles of individual compounds provides a framework for thinking about which combinations are likely to be relatively safe and which require more caution.
The general principle is that compounds sharing pharmacological targets can elicit additive or synergistic effects—meaning their combined effect is equal to or greater than the sum of their individual effects. This can be beneficial when both compounds are neuroprotective, but could be problematic if the shared effect carries a dose-dependent risk.
Racetam-class nootropics—including piracetam, aniracetam, phenylpiracetam, and oxiracetam—primarily act by modulating AMPA glutamatergic receptors and the cholinergic system. Semax also demonstrates documented activity at metabotropic glutamate receptors [14] and modulates cholinergic receptor binding [15], suggesting these compounds share some pharmacological territory. In comparative nootropic studies, Semax and piracetam have been tested side-by-side in amnesia models [16] without reporting dramatic adverse interactions. Combining racetams with Semax is likely among lower-risk nootropic combinations based on pharmacological overlap, though direct safety data for combinations remain absent.
Phenylpiracetam is a more stimulating variant of the racetam class, with additional stimulant-like properties. Combining it with Semax's dopamine-enhancing effects creates more theoretical overlap with the stimulant interaction concerns discussed above. The more stimulating the nootropic compound being considered, the more significant the concern about dopaminergic amplification becomes.
Does Semax interact with NAD+ or NAD+ precursors?
No published studies have investigated the combination of Semax with NAD+ precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). NAD+—nicotinamide adenine dinucleotide—is a molecule that plays a key role in cellular energy production. NAD+ precursors are supplements taken to boost NAD+ levels in the body, supporting mitochondrial function, DNA repair, and healthy aging.
NAD+ precursors primarily act.
Both Semax and NAD+ precursors affect mitochondrial function. Semax does this via BDNF-driven neuroprotection involving mitochondrial membrane stabilization [17], while NAD+ directly supports the electron transport chain—a biochemical process within mitochondria that produces cellular energy. Whether these effects are simply additive or involve more complex interactions has not been investigated. This combination cannot be characterized as safe or unsafe based on available evidence.
Does Semax interact with thyroid medication?
No published research has examined the interaction of Semax with thyroid medications such as levothyroxine or liothyronine—synthetic thyroid hormones commonly prescribed for hypothyroidism. Thyroid hormones exert a broad influence on brain function, neurotransmitter receptor sensitivity, and overall metabolic rate—all of which could theoretically affect how Semax behaves in the body.
Thyroid hormones affect BDNF expression, serotonin receptor sensitivity, and dopaminergic function in a manner that overlaps with Semax's pharmacological targets, making this combination theoretically complex, even in the absence of direct interaction data. Individuals on thyroid medication considering Semax should discuss this with their endocrinologist—especially if they have been recently diagnosed or are still finding a stable medication dosage.
Does Semax interact with supplements?
Most common dietary supplements—including standard vitamins, minerals, fish oil, and basic herbal supplements—are unlikely to significantly interact with Semax, given the absence of shared receptor targets with its known mechanisms.
A few specific supplements warrant more careful consideration. St. John's Wort - an herbal supplement that acts as a natural serotonin reuptake inhibitor, using a similar mechanism to pharmaceutical SSRIs - should be combined with Semax with the same caution as pharmaceutical SSRIs, due to the theoretical risk of additive serotonergic effects.
Supplements with significant dopaminergic activity—such as mucuna pruriens, a plant extract containing L-DOPA (a direct dopamine precursor), or high doses of tyrosine—interact with the same dopaminergic circuits that Semax sensitizes. The concern regarding dopaminergic potentiation discussed in the section on stimulants also applies here, though likely with less force due to the more modest dopaminergic effects of these supplements compared to prescription medications.
Supplements with anticoagulant properties — including high-dose fish oil, vitamin E, ginkgo biloba, and garlic extracts — could theoretically add to Semax's own fibrinolytic and antiplatelet effects [12], creating a small but real additive bleeding risk. This concern is amplified if these supplements are also combined with prescribed blood-thinning medications.
Can Semax be safely combined with Selank?
The combination of Semax and Selank is the most studied combination in the literature for Semax — though this needs to be understood in context: it means that both peptides have been studied in overlapping populations and analyzed side-by-side in specific studies, rather than in dedicated pharmacokinetic interaction studies specifically designed to assess co-administration safety.
Brain imaging functional connectivity research analyzed both peptides in the same group of 52 healthy participants [18], and enkephalinase inhibition research—which analyzes how well each peptide inhibits enzymes that break down natural calming brain peptides—tested both peptides simultaneously in the same human serum samples [5]. This provides the closest available data on their combined pharmacological actions.
Both peptides inhibit the enzymes that break down enkephalins in human serum. Semax does so with an IC50 of 10 micromoles, and Selank with an IC50 of 20 micromoles [5]. IC50 is a standard measure representing the concentration required to achieve 50% inhibition. Their combination would be expected to result in greater overall inhibition of these enzymes—meaning that the brain’s natural enkephalins would remain active longer—than either compound alone. This additive effect on the enkephalin system is worth noting, although it has not been associated with adverse outcomes in the published literature.
The general pharmacological compatibility of Semax and Selank appears reasonable based on their complementary profiles—Semax being more activating and nootropic, Selank more sedating and anxiolytic—and the lack of reported adverse interactions in Russian clinical literature where both are used. However, formal pharmacokinetic and pharmacodynamic interaction studies—studies specifically designed to measure how two compounds affect each other’s behavior in the body—have not been published for this combination. Characterizing their combination as compatible rests on the absence of reported problems, rather than demonstrated safety through controlled study.
What is the general risk profile of Semax drug interactions?
The general risk profile of drug interactions for Semax can be summarized at three levels based on the pharmacological strength of concern.
Interactions of greatest concern—where concrete documented evidence provides a mechanistic basis for genuine caution—involve amphetamine-based stimulants, due to a demonstrated dopaminergic-reinforcing effect in animal studies [9], and anticoagulants, due to Semax's own fibrinolytic and antiplatelet activity [12].
Interactions that cause moderate concern — where pharmacologic overlap creates a plausible but unproven risk of interaction — include SSRIs and other serotonergic agents, other stimulants and dopaminergic supplements, blood pressure medications, antiseizure medications for seizure disorders, and thyroid medications.
The lower concern category — where significant pharmacological overlap is absent and interaction risk appears theoretically limited — includes most standard vitamins, minerals, and non-psychoactive supplements, as well as the Semax-Selank combination based on their relatively complementary pharmacological profiles.
This risk stratification relies solely on pharmacological reasoning from individual compound studies, not formal drug-drug interaction studies. The appropriate response to this evidence gap is not to continue combining under the assumption of safety. Instead, consulting with a healthcare professional who can assess the individual's medical context—including existing comorbidities, concomitant medications, and personal risk factors—before combining Semax with any prescription medication or high-dose supplement, is the most medically sound approach.
Disclaimer
This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a claim regarding the safety or efficacy of Semax for the treatment of any medical condition. Semax remains an investigational compound in most countries, including the United States and most European countries, and is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. Most of the evidence presented in this article is derived from preclinical animal studies and a limited number of human clinical trials. Additional, well-designed clinical trials are needed to more definitively establish the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans.
References
Shypshyna, M. S., Veselovsky, N. S., Myasoedov, N. F., Shram, S. I., & Fedulova, S. A. (2015). Effect of peptide Semax on synaptic activity and short-term plasticity of glutamatergic synapses of co-cultured dorsal root ganglion and dorsal horn neurons. Physiological Journal, 61(4), 48–55. https://doi.org/10.15407/fz61.04.048
Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[3] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
[4] Lebedeva, I. S., Panikratova, Ya. R., Sokolov, O. Yu., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165(5), 653–656. https://doi.org/10.1007/s10517-018-4234-3
Kost, N. V., Sokolov, O. Yu., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. A., Miasoedov, N. F., & Zozulia, A. A. (2001). Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorganic Chemistry, 27(3), 180–183. https://doi.org/10.1023/a:1011373002885
Shadrina, M. I., Dolotov, O. V., Grivennikov, I. A., Slominsky, P. A., Andreeva, L. A., Inozemtseva, L. S., Limborska, S. A., & Myasoedov, N. F. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience Letters, 308(2), 115–118. https://doi.org/10.1016/s0304-3940(01)01994-2
[7] Vilenskiĭ, D. A., Levitskaia, N. G., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2007). Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats. Sechenov Physiological Journal of Russia, 93(6), 661–669. PMID: 17850024
Glazova, N. Yu., Manchenko, D. M., Volodina, M. A., Merchieva, S. A., Andreeva, L. A., Kudrin, V. S., Myasoedov, N. F., & Levitskaya, N. G. (2021). Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides, 86, 102114. https://doi.org/10.1016/j.npep.2020.102114
[9] Eremin, K. O., Saransaari, P., Oja, S., & Raevskiĭ, K. S. (2004). Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice. Experimental and Clinical Pharmacology, 67(2), 8–11. PMID: 15188751
[10] Arushanian, E. B., & Popov, A. V. (2009). Effect of semax on heart rate variability in various daytime periods. Experimental and Clinical Pharmacology, 72(2), 32–34. PMID: 19441725
Gorbacheva, A. M., Berdalin, A. B., Stulova, A. N., Nikogosova, A. D., Lin, M. D., Buravkov, S. V., Gavrilova, S. A., & Koshelev, V. B. (2016). Changes in sympathetic innervation of rat caudal artery in experimental myocardial infarction: Effect of Semax peptide. Bulletin of Experimental Biology and Medicine, 161(4), 476–480. https://doi.org/10.1007/s10517-016-3442-y
[12] Grigorjeva, M. E., & Lyapina, L. A. (2010). Anticoagulation and antiplatelet effects of semax under conditions of acute and chronic immobilization stress. Bulletin of Experimental Biology and Medicine, 149(1), 44–46. https://doi.org/10.1007/s10517-010-0871-x
Alekseeva, G. V., Bottaev, N. A., & Goroshkova, V. V. (1999). Use of semax at a follow-up of patients with posthypoxic encephalopathy. Anesthesiology and Resuscitation, (1), 40–43. PMID: 10199046
Firstova, Yu. Yu., Vasil’eva, E. V., & Kovalev, G. I. (2011). Studying specific effects of nootropic drugs on glutamate receptors in the rat brain. Experimental and Clinical Pharmacology, 74(1), 6–10. PMID: 21476267
Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., & Myasoedov, N. F. (2019). An integrated approach to study the molecular aspects of regulatory peptides biological mechanism. Journal of Labeled Compounds & Radiopharmaceuticals, 62(12), 812–822. https://doi.org/10.1002/jlcr.3785
[16] Iasnetsov, V. V., & Voronina, T. A. (2009). Effect of Semax and Mexidol on brain ischemia models in rats. Experimental and Clinical Pharmacology, 72(1), 68–70. PMID: 19334516
17. Storozhevykh, T. P., Tukhbatova, G. R., Senilova, Ya. E., Pinelis, V. G., Andreeva, L. A., & Myasoyedov, N. F. (2007). Effects of Semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity. Bulletin of Experimental Biology and Medicine, 143(5), 601–604. https://doi.org/10.1007/s10517-007-0192-x
[18] Panikratova, Ya. R., Lebedeva, I. S., Sokolov, O. Yu., Rumshiskaya, A. D., Kupriyanov, D. A., Kost, N. V., & Myasoedov, N. F. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X